The study find that the ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized patients with de novo three-vessel and left main coronary artery disease, according to late breaking results from the SYNTAX Extended Survival study presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology and published in The Lancet. Therefore Prespecified subgroup analyses showed that surgery provided a survival benefit in patients with three-vessel disease and more complex coronary artery disease, while no treatment differences were found in patients with left main disease.
Similar for bypass surgery
Ischaemic heart disease is the top cause of death globally. Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are options for patients requiring revascularization. But European guidelines advise discussing these patients in a multidisciplinary Heart Team. Individual randomized trials comparing PCI with drug-eluting stents and CABG have not shown a survival benefit for either therapy at mid-term follow-up; (e.g. up to five years).
The SYNTAX trial was the first large-scale multicenter; randomized study in patients with de novo three-vessel and left main coronary artery disease that underwent PCI with drug-eluting stents or CABG. When clinical equipoise between PCI and CABG is presume by the Heart Team; 1,800 patients are randomly assign to PCI with paclitaxel-eluting stents (n=903) or CABG (n=897). Survival curves started to diverge after one-year follow-up and continue to diverge up to five years; but without reaching statistical significance.
The SYNTAX Extended Survival (SYNTAXES) study examined 10-year all-cause death rates in patients with de novo three-vessel and left main coronary artery disease randomized to PCI with drug-eluting stents or CABG in the SYNTAX trial. Because All 85 SYNTAX sites from 18 North American and European countries are contact to provide survival data, which is obtain from healthcare records and national death registries. Completeness of follow-up was achieved in 94% of patients and was well-balanced between the CABG and PCI arms.
At 10-year follow-up, there was no survival difference between PCI with drug-eluting stents and CABG in the overall cohort of patients. There were 244 deaths after PCI and 211 after CABG (hazard ratio [HR] 1.17; 95% confidence interval [CI] 0.97–1.41; p=0.092). When analyses were conduct according to prespecify subgroups; CABG provided a 10-year survival benefit over PCI in patients with three-vessel disease ;(151 deaths after PCI versus 113 after CABG; HR 1.41; 95% CI 1.10–1.80; p=0.006). CABG also provided a survival benefit in patients with increasingly complex coronary artery disease (defined by higher SYNTAX scores); this is observe in the overall cohort and in those with three-vessel disease.
In the subgroup of patients with left main coronary artery disease, no survival differences existed between PCI and CABG ;(93 patients died after PCI versus 98 after CABG; HR 0.90; 95% CI 0.68–1.20; p=0.47). This resulted in a treatment-by-subgroup interaction according to the presence or absence of left main coronary artery disease (p for interaction=0.019). Furthermore; CABG and PCI resulted in comparable 10-year survival in patients with and without diabetes.